Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives
Open Access
- 1 January 2012
- journal article
- review article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 1 (1), 3-9
- https://doi.org/10.5582/irdr.2012.v1.1.3
Abstract
Rare diseases are an important public health issue and a challenge to medical care. Specific legislation to encourage research of rare diseases and development of orphan drugs has been adopted in the United States (US), the European Union (EU), and elsewhere. In recent years, much progress has been made in some parts of Asia, including Japan, South Korea, and Taiwan, with the enactment of legislation and accompanying regulation of rare diseases and orphan drugs. China is also actively promoting the regulation of rare diseases and orphan drugs. We describe the current status of the regulation of rare diseases and orphan drugs in Asia and we comparatively analyze the regulation of rare diseases and orphan drugs worldwide in order to examine the challenges to and future perspectives on promoting research on rare diseases and development of orphan drugs in China and other Asian countries.Keywords
This publication has 18 references indexed in Scilit:
- European regulation on orphan medicinal products: 10 years of experience and future perspectivesNature Reviews Drug Discovery, 2011
- Rare diseases and orphan drugsPublished by Istituto Superiore di Sanita ,2011
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010
- Call for a national plan for rare diseasesJournal of Paediatrics and Child Health, 2010
- Why rare diseases are an important medical and social issueThe Lancet, 2008
- Empowerment of patients: lessons from the rare diseases communityThe Lancet, 2008
- Rare diseases: what's next?The Lancet, 2008
- Orphan drug legislation: lessons for neglected tropical diseasesThe International Journal of Health Planning and Management, 2008
- Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory pricesCMAJ : Canadian Medical Association Journal, 2006